Atopic dermatitis global market report showcases that the market will grow at a CAGR of 8.2% during the forecast period of 2017-2023. According to the report published by the National Center for Biotechnology Information, and atopic dermatitis has affected around 20% of infants and children and 3% of adults at a global level. There has been rising funding along with government support for the research and development boosting the growth of the atopic dermatitis market.
Atopic Dermatitis is one of the most common types of eczema that is with the patients who suffer from this disease and have super sensitive skin and a reduced threshold for irritation. It misguides the immune system in the body and leads to the development of chronic diseases. The prevalence of atopic dermatitis has increased all over the world and mostly it has been affecting infants and children.
Atopic dermatitis is one of the most common but severe types of eczema, which causes red, itchy rash usually on the arms, cheeks, and legs. It makes the patient’s skin and immune system extremely sensitive and reactive to the smallest allergens or irritants. Atopic dermatitis most commonly affects children and infants, and studies show that in recent years, one of the major causes for its prevalence is air pollution.
Atopic Dermatitis is one of the most common types of eczema that is with the patients who suffer from this disease and have super sensitive skin and a reduced threshold for irritation. It misguides the immune system in the body and leads to the development of chronic diseases. The prevalence of atopic dermatitis has increased all over the world and mostly it has been affecting infants and children
The global atopic dermatitis market has been presented with the growing rate of the global market at a faster rate. The report also presents a detailed analysis of dermatitis that can be segmented based on the types, applications, and the end-users.
On the basis of the type, the global market can be split into:
- Monoclonal antibodies
And based on the applications, the global atopic dermatitis market can be classified into:
- Chronic diseases
- Blood disorders
- Infectious diseases
And on the basis of the end user, the global atopic dermatitis market can be classified into:
- Research centers
North America is the dominant region in the global atopic dermatitis market and has been assessed to lead the market over the forecast period, owing to the extensive investment in the healthcare sector, government expenditure towards healthcare research and development for advancement, growing usage of cosmetics and perfumes which lead to skin irritation, and the increasing patient population.
Europe has been accounted for the second-largest market share in the global atopic dermatitis market. The market has been assessed to grow significantly due to the increasing expenditure in stable economies such as France and Germany on healthcare and ensures the affordability of high-quality medical care by consumers owing to their steady disposable income.
The Asia Pacific has been assessed as the fastest-growing region in the global atopic dermatitis market, owing to the increasing healthcare expenditure by the governments in emerging economies such as China, and India, to provide consumers with better medical facilities.
The key players in the global atopic dermatitis market are Anacor Pharmaceuticals Inc. (U.S.), Bristol-Myers Squibb (U.S.), Meda Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S.), Valeant Pharmaceuticals International, Inc (Canada), Allergan Plc. (Republic of Ireland), Astellas Pharma Inc. (Japan), Galderma S.A. (Switzerland), Novartis International AG (Switzerland), Sanofi S.A. (France), and others.